(1) known or suspected allergy to the components of Azivudine tablets, (2) patients with malabsorption syndrome or any other condition that affects gastrointestinal absorption and requires intravenous nutrition or unable to take oral medication, (3) patients who is currently receiving anti-hiv treatment, (4) patients with one of the following conditions: respiratory failure and mechanical ventilation,Shock,Combined with other organ failure, intensive care unit(ICU) was needed. (5) women who are pregnant or breast-feeding or have a family planning plan during the trial period and within 6 months after the end of the trial, (6) participating in another clinical trials or using experimental drugs within 12 weeks prior to administration, (7) there are other conditions that are not suitable for participating in this experiment evaluated by the investigator.

(1) known or suspected allergy to the components of Azivudine tablets, (2) patients with malabsorption syndrome or any other condition that affects gastrointestinal absorption and requires intravenous nutrition or unable to take oral medication, (3) patients who is currently receiving anti-hiv treatment, (4) patients with one of the following conditions: respiratory failure and mechanical ventilation,Shock,Combined with other organ failure, intensive care unit(ICU) was needed. (5) women who are pregnant or breast-feeding or have a family planning plan during the trial period and within 6 months after the end of the trial, (6) participating in another clinical trials or using experimental drugs within 12 weeks prior to administration, (7) there are other conditions that are not suitable for participating in this experiment evaluated by the investigator.